➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKesson
Moodys
Medtronic
Boehringer Ingelheim

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GATIFLOXACIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for gatifloxacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00216385 ↗ A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status European Commission Phase 3 2005-01-01 Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,
NCT00216385 ↗ A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status World Health Organization Phase 3 2005-01-01 Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,
NCT00216385 ↗ A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status Institut de Recherche pour le Developpement Phase 3 2005-01-01 Tuberculosis is currently treated with a 6-month course regimen. During this time many patients might fail to adhere to treatment and default, increasing the risk of recurrent disease which might be multidrug resistant. A shorter duration of treatment is expected to provide improved patient compliance and at least equal or better clinical outcome. The aim of the trial is to evaluate the efficacy and safety of a gatifloxacin-containing regimen of four months duration for the treatment of pulmonary tuberculosis,
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for gatifloxacin

Condition Name

Condition Name for gatifloxacin
Intervention Trials
Bacterial Conjunctivitis 5
Cataract 3
Dysglycemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for gatifloxacin
Intervention Trials
Cataract 6
Conjunctivitis, Bacterial 6
Conjunctivitis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for gatifloxacin

Trials by Country

Trials by Country for gatifloxacin
Location Trials
United States 15
Brazil 5
Canada 2
India 2
Pakistan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for gatifloxacin
Location Trials
California 5
New York 2
South Carolina 1
Kentucky 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for gatifloxacin

Clinical Trial Phase

Clinical Trial Phase for gatifloxacin
Clinical Trial Phase Trials
Phase 4 9
Phase 3 6
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for gatifloxacin
Clinical Trial Phase Trials
Completed 17
Recruiting 4
Unknown status 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for gatifloxacin

Sponsor Name

Sponsor Name for gatifloxacin
Sponsor Trials
Allergan 5
Bausch & Lomb Incorporated 4
Stanford University 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for gatifloxacin
Sponsor Trials
Other 31
Industry 13
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
Dow
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.